Company Overview and News

9
Chaparral Energy Appoints David Geenberg to Board of Directors

2018-06-07 globenewswire
OKLAHOMA CITY, June 07, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (OTCQB:CHPE) today announced that it has expanded its board of directors from seven to eight members and has appointed David Geenberg as a new independent member of the board, effectively immediately. Chaparral’s board, with the addition of Geenberg, now includes eight members, of which seven serve as independent directors. Shareholders of record will have the opportunity to re-elect all of the company’s directors at its upcoming annual meeting, which will be held on June 29, 2018.
CHPE PVAC PVAYQ PVA SBOW

0
CHPE / Chaparral Energy Inc 8-K (Current Report)

2018-06-07 sec.gov
chpe-8k_20180606.htm UNITED STATES
CHPE

0
CHPE / Chaparral Energy Inc 8-K (Current Report)

2018-05-18 sec.gov
chpe-8k_20180516.htm UNITED STATES
CHPE

0
Chaparral Energy Announces First Quarter 2018 Financial and Operational Results

2018-05-10 globenewswire
OKLAHOMA CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (OTC:CHPE) today announced its first quarter 2018 financial and operational results with the filing of its form 10-Q. The company will hold its quarterly financial and operating results conference call this morning, May 10, at 9 a.m. Central.
CHPE

0
CHPE / Chaparral Energy Inc 8-K (Current Report)

2018-05-10 sec.gov
chpe-8k_20180510.htm UNITED STATES
CHPE

0
CHPE / Chaparral Energy Inc 10-Q (Quarterly Report)

2018-05-10 sec.gov
chpe-10q_20180331.htm UNITED STATES
CHPE

0
CHPE / Chaparral Energy Inc 424B3 (Prospectus)

2018-05-04 sec.gov
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-218579 PROSPECTUS Chaparral Energy, Inc.
CHPE

2
CHPE / Chaparral Energy Inc FORM 10-K/A (Annual Report)

2018-04-30 sec.gov
Form 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C
CHPE

0
Chaparral Energy Schedules First Quarter 2018 Earnings Release Date and Conference Call

2018-04-26 globenewswire
OKLAHOMA CITY, April 26, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (OTCQB:CHPE) today announced that it will issue its first quarter 2018 financial and operational results with the filing of its 10-Q report on Thursday, May 10, 2018. The company will also host a conference call to discuss its results that morning at 9 a.m. Central.
CHPE

0
CHPE / Chaparral Energy Inc POS AM

2018-04-20 sec.gov
POS AM Table of Contents As filed with the Securities and Exchange Commission on April 20, 2018 Registration No. 333-218579
CHPE

16
Oasis Petroleum (OAS) in Focus: Stock Moves 10.6% Higher

2018-04-19 zacks
Oasis Petroleum Inc.(OAS - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 27.7% in the past one-month time frame.
CHPE OAS WDC

0
CHPE / Chaparral Energy Inc 8-K (Current Report)

2018-04-10 sec.gov
chpe-8k_20180410.htm UNITED STATES
CHPE

0
CHPE / Chaparral Energy Inc 10-K (Annual Report)

2018-03-29 sec.gov
chpe-10k_20171231.htm
CHPE

0
CHPE / Chaparral Energy Inc 8-K (Current Report)

2018-03-29 sec.gov
chpe-8k_20180329.htm UNITED STATES
CHPE

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to CHPE / Chaparral Energy Inc on message board site Silicon Investor.

Blue Chip Computerware (BCHPE)